Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial - Concepedia

Concepedia

Publication | Open Access

Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial

DOI Full Paper Access

84

Citations

11

References

2019

Year

Mark E. Robson, Kathryn J. Ruddy, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Wei Li, Nadine Tung, Anne Armstrong,

European Journal of Cancer

Abstract

HRQoL was consistently improved for patients treated with olaparib, compared with chemotherapy TPC.

References

	Year	Citations

Page 1